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Abstract 
Background: The role of Wnt signalling in carcinogenesis suggests compounds targeting this 
pathway as potential anti-cancer drugs. Several studies report activation of Wnt signalling in 
biliary tract cancer (BTC) thus rendering Wnt inhibitory drugs as potential candidates for 
targeted therapy of this highly chemoresistant disease. 
Methods: In this study we analysed five compounds with suggested inhibitory effects on Wnt 
signalling (DMAT, FH535, myricetin, quercetin, and TBB) for their cytotoxic efficiency, mode 
of cell death, time- and cell line-dependent characteristics as well as their effects on Wnt 
pathway activity in nine different BTC cell lines. 
Results: Exposure of cancer cells to different concentrations of the compounds results in a 
clear dose-dependent reduction of viability for all drugs in the order FH535 > DMAT > TBB 
> myricetin > quercetin. The first three substances show high cytotoxicity in all tested cell 
lines, cause a direct cytotoxic effect by induction of apoptosis and inhibit pathway-specific 
signal transduction in a Wnt transcription factor reporter activity assay. Selected target genes 
such as growth-promoting cyclin D1 and the cell cycle progression inhibitor p27 are down- 
and up-regulated after treatment, respectively.  
Conclusions: Taken together, these data demonstrate that the small molecular weight in-
hibitors DMAT, F535 and TBB have a considerable cytotoxic and possibly Wnt-specific effect 
on BTC cell lines in vitro. Further in vivo investigation of these drugs as well as of new Wnt 
inhibitors may provide a promising approach for targeted therapy of this difficult-to-treat 
tumour. 
Key words: Biliary Tract Cancer, Wnt pathway, pharmacological inhibition, Cytotoxicity, Apoptosis 
Introduction 
The Wnt pathway represents a conserved cellu-
lar signalling mechanism involved in various steps of 
embryonic  development  and  stem  cell  regulation      
[1, 2]. A broad range of functional studies revealed 
that  this  pathway  also  contributes  to  malignant  be-
haviour by augmenting tumour cell proliferation [3], 
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anti-apoptosis  signalling  [4],  and  invasion  by  pro-
moting  epithelial-to-mesenchymal  transition  [5]. 
Furthermore,  survival  and  maintenance  of  highly 
tumourigenic  cancer  stem  or  cancer-initiating  cell 
subpopulations have been linked to active Wnt sig-
nalling  in  analogy  to  their  physiologic  stem  cell 
counterpart  [6]. Therefore, inhibition of Wnt signal-
ling  pathway  represents  an  attractive  therapeutic 
target for many human cancer types [7]. 
The prognosis of patients with biliary tract can-
cer (BTC) is still poor due to limited therapeutic op-
tions [8]. A recently published phase III randomised 
trial proved a moderate benefit of cisplatin plus gem-
citabine chemotherapy in advanced BTC (median 11.7 
months overall survival compared to 8.1 months of 
the  gemcitabine  standard  arm)  [9].  Photodynamic 
therapy is established for local treatment of advanced 
hilar BTCs [10]. Nevertheless, identification of molec-
ular  oncogenic  mechanisms  amenable  to  targeted 
therapy is highly needed for this tumour type to more 
significantly improve the patient’s prognosis [11]. 
Canonical Wnt signal transduction is based on 
paracrine signals by Wnt ligands (19 members) which 
are registered at the receiving cell by plasma mem-
brane  receptors  (frizzled  receptors  and  low  density 
lipoprotein receptor-related protein, LRP) resulting in 
stabilisation of cytoplasmatic -catenin proteins and 
its subsequent nuclear translocation and transcription 
regulation  by  interaction  with  members  of  the 
TCF/LEF family (T-cell specific transcription factor, 
lymphoid-enhancer  binding  factor  1).  In  absence  of 
Wnt ligands, -catenin is degraded by the cytoplas-
matic  destruction  complex  consisting  of  multiple 
proteins such as APC (adenomatous polyposis coli), 
axin2,  casein  kinase-2  (CK2)  and  GSK3  (glycogen 
synthase kinase 3) [12, 13]. In a recent study we re-
ported  correlation  of  active  Wnt  signalling  as  indi-
cated by cytoplasmatic and nuclear localisation of the 
Wnt effector protein -catenin with cellular prolifera-
tion (cyclin-D1 and Ki67 expression) both in vitro and 
in vivo in human BTC [14].  
Based on these findings, and other reported al-
terations of Wnt / -catenin signalling in BTC [15-17] 
this study analysed the cytotoxic efficiency and cel-
lular mechanisms of several small molecular weight 
drugs with suggested inhibitory effects on Wnt sig-
nalling in nine different BTC cell lines. The inhibitors 
DMAT  (2-dimethylamino-4,5,6,7-tetrabromo-1H- 
benzimidazole;  CK2  inhibitor  [18]),  FH535  (dual 
PPAR  and  -catenin  inibitor  [19]),  myricetin  and 
quercetin  (flavonoids),  and  TBB 
(4,5,6,7-tetrabromo-2-azabenzimidazole,  CK2  inhibi-
tor) were tested for their dose- and cell line-dependent 
cytotoxic effects on BTC cells in vitro. The compounds 
were chosen either i) referring to their ability to inhibit 
casein kinase II (DMAT, TBB) which is required for 
active Wnt signalling [20, 21], or ii) because of a re-
ported inhibitory effect on -catenin / TCF-mediated 
transcription  (FH535  [19],  quercetin  and  myricetin 
[22-24]).  Apoptosis  detection  by  caspase  activation 
and nuclear fragmentation, time-dependent cytotoxi-
city and cell cycle analysis were used to investigate 
the  cellular  mechanisms  of  toxicity.  Furthermore, 
specific  effects  on  Wnt  signal  transduction  and  ex-
pression  of  Wnt  pathway  targets  were  analysed  by 
reporter  gene  assays  and  target  mRNA  /  protein 
quantification, respectively. In brief, the results indi-
cate differential effects of these inhibitors on prolifer-
ation and direct cytotoxic effects by apoptosis induc-
tion  in  BTC  cells.  The  results  suggest  that  DMAT, 
FH535, and TBB show considerable cytotoxicity in our 
BTC in vitro model system which might partly rely on 
their ability to inhibit Wnt signal transduction. Sub-
sequent  preclinical  testing  of  these  drugs  seems 
promising while elucidation of the specific mode of 
action  and  pathway  specificity  requires  additional 
in-depth analyses.  
Materials and Methods 
Substances and cell culture  
Resazurin  sodium  salt,  propidium  iodide, 
RNAse  and  the  Wnt  pathway  inhibitors  (DMAT, 
FH535, Myricetin, Quercetin, and TBB) were obtained 
from  Sigma-Aldrich  (Vienna,  Austria).  Biliary  tract 
cancer cell lines included CCLP-1(G3, original tumour 
grading),  CCSW-1(G2),  BDC(G4),  Egi-1(G3), 
SkChA-1(G3), TFK-1(G2), derived from bile duct car-
cinoma and MzChA-1(G1), MzChA-2(G2), GBC(G1), 
derived  from  gallbladder  cancer  (see  [14]  for  refer-
ences) and were cultured as described previously [14, 
25] in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented  with  10%  (v/v)  foetal  bovine  serum 
(FBS;  PAA  Laboratories,  Pasching,  Austria).  For  in-
cubation  with  Wnt  inhibitors,  serum-free  DMEM 
(sfDMEM)  was  used  to  avoid  interactions  between 
serum  components  and  the  compounds.  For  all  ex-
perimental setups in different cell culture receptacles, 
cells within 10 passages were seeded at cell densities 
of 3.68*104 cm-2 (for CCLP-1, BDC, MzChA-2), 4.41*104 
cm-2 (for CCSW-1, GBC), 5.15*104 cm-2 (for SkChA-1), 
5.88*104 cm-2 (for Egi-1, TFK-1), and 6.62*104 cm-2 (for 
MzChA-1) in 10% FBS DMEM.  
Viability analysis 
Dose-dependent cytotoxicity was measured us-
ing  CCLP-1  cells  in  96-well  microplates  using  the 
resazurin assay as described previously [25]. This test 
involves  incubation  of  cells  with  the  blue,  weakly Int. J. Biol. Sci. 2012, 8 
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fluorescent resazurin which is converted to the pink, 
highly fluorescent resorufin catalysed by cellular de-
hydrogenase  enzymes  and  cytochromes.  Therefore, 
the rate of dye reduction monitored by the change in 
fluorescence reflects the number of viable cells in a 
sample [26]. Twenty-four hrs after seeding, the cells 
were washed once with sfDMEM and incubated with 
a serial dilution of the respective inhibitor in sfDMEM 
for 72 hrs. Afterwards, the cellular viability signal was 
measured using the resazurin assay as described pre-
viously [25] using an Infinite M200 microplate reader 
at EX=535 nm / EM=588 nm (Tecan, Groedig, Aus-
tria). Similarly, cytotoxicity of a constant concentra-
tion of each inhibitor (10 µM for DMAT and TBB, 20 
µM for FH535, and 50 µM for Myricetin and Querce-
tin) was measured for all BTC cell lines and related to 
untreated control cells (100% viability). For analysis of 
the kinetics of the viability signal, CCLP-1 cells were 
treated  and  processed  in  96-well  microplates  using 
the resazurin assay as described above at 0, 24, 48, and 
72 hrs post incubation. All values are related to the 
initial value of each treatment (or control, i.e. 100% or 
‘1’ in Figure 3 A, B).  
Real-time cell viability analysis 
The  xCELLigence  system  (Roche  Applied  Sci-
ence,  Mannheim  Germany)  was  used  for  real-time 
and time-dependent analysis of the cellular response 
of CCLP-1 cells (Fig. 3 C, D). Using specifically de-
signed microplates, this system measures the cellular 
impedance  which  is  dependent  on  the  level  of  cell 
confluence and is defined as (Rn-Rb)/(15Ω), where Rn 
is the cell-electrode impedance of the well containing 
cells and Rb is the background impedance of the well 
with medium alone. This value is expressed by the 
cell index which itself reflects the number of cells at-
tached to and spreading on the bottom of the micro-
plate wells. Changes in the cell index, therefore, mir-
ror the number of viable cells as apoptotic cells round 
up  and  loose  contact  to  the  substrate  [27].  In  brief, 
7200  cells  per  well  were  seeded  in  96-well  E-plates 
(Roche Applied Science; in 150 µl 10% FBS DMEM), 
washed once with 150 µl sfDMEM after 24 hrs and 
incubated with four different concentrations of TBB 
and myricetin. The cell index was calculated relative 
to  untreated  control  cells  set  at  100%.  Values  were 
normalised to the time point of treatment and con-
tinuously measured every 15 s (0-6 hrs), 60 s (6-18 hrs) 
or every 15 min (18-72 hrs). For better readability error 
bars are shown only for the 65th (within 0-6 hrs), 25th 
(6-18 hrs) and 4th (18.5-72 hrs) data point. Data anal-
ysis  was  performed  using  the  RTCA  software  1.2.1 
(Roche) for calculating the temporal dynamics of cell 
index changes and IC50 values of each drug. 
Apoptosis detection 
Measurement  of  caspase-3/7  activity  was  per-
formed at 0, 10, 24, and 32 hrs post incubation using 
the luminometric Caspase-Glo 3/7 Assay (Promega, 
Mannheim,  Germany)  and  the  Infinite  M200 reader 
according to the manufacturer’s instructions and re-
lated to the total protein content (bicinchoninic acid 
assay; Thermo Scientific, Vienna, Austria) to normal-
ise for variations in the cell number (Fig. 4 A, B). Cell 
cycle  analysis  (Fig.  5)  was  performed  with  etha-
nol-fixed,  RNase-treated  and  propidium  io-
dide-stained  cells  following  48  hrs  after  incubation 
with each inhibitor using a Dako Galaxy flow cytom-
eter (Dako, Glostrup, Denmark) and analysed using 
Partec’s FloMax software (Partec, Görlitz, Germany). 
Furthermore,  cells  were  analysed  24  hrs  after  treat-
ment by phase contrast microscopy (Fig. 4E) and flu-
orescence  microscopy  (Fig.  4F)  following  nuclear 
staining with Hoechst 33342 (5 µg/ml for 15 min at 
37°C) using an IX70 inverted fluorescence microscope 
(Olympus, Vienna, Austria) equipped with a DFC425 
C digital camera (Leica Mikrosysteme, Vienna, Aus-
tria). 
Effect of Wnt inhibitors on specific Wnt re-
porter transcription 
Using  the  Cignal  reporter  assay  kit  (SABiosci-
ences, Frederick, MD, USA), the inhibitory effect of 
each compound on the expression of a luciferase re-
porter gene under the control of TCF/LEF transcrip-
tional  response  element  was  investigated  in  CCLP 
cells. In brief, cells were transfected with the reporter 
or control constructs and then exposed to the inhibi-
tory substances for 6 hrs. Afterwards cells were lysed 
and  measured  using  the  Dual  Luciferase  Reporter 
assay  (Promega)  in  the  therefor  certified  Infinite 
M-200 reader. The two luminescence values obtained 
after injection of the respective substrates indicate the 
specific reporter signal (firefly luciferase, ‘FF’) and the 
internal  control  signal  (renilla  luciferase,  ‘RR’)  ex-
pressed as ratios (FF/RR) to correct for variations in 
transfection efficiency or cell number.  
Real-time reverse transcription PCR of Wnt 
pathway targets 
Cells  were  seeded  in  6  cm  culture  dishes  and 
treated  with  single  concentrations  of  the  inhibitors 
and lysed after 5 or 24 hrs by addition of Trizol rea-
gent (Invitrogen, Lofer, Austria). Total RNA was iso-
lated,  purified  by  RNase-free  DNase  (Promega, 
Mannheim, Germany) and reverse transcribed using 
the  ImProm-II  RT  system  (Promega)  with  random 
primers  (Invitrogen),  all  according  to  the  manufac-
turer’s  instructions.  Quantitative  real-time  reverse Int. J. Biol. Sci. 2012, 8 
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transcriptase-PCR (qRT-PCR) was employed to ana-
lyse expression of Wnt target genes (cyclin D1, p27, 
vimentin, E-Cadherin, -catenin, axin2, TCF7L1, and 
TCF7L2) using the ViiA 7 real-time PCR thermocylcer 
(Applied  Biosystems,  Vienna  Austria).  Identity  and 
specificity  of  the  product  was  checked  by  agarose 
gel-electrophoresis  and  by  negative  first-deviation 
plots of the melting curve, respectively. Calculation of 
the  relative  expression  of  each  transcript  (X)  was 
performed  using  the  formula  2-Ct  [14,  28],  where 
Ct=Ct(x)-Ct(housekeeping  gene) with  -actin  as  the  house-
keeping gene. For primer sequences see Supplemen-
tary Material: Table S1.  
Immunochemistry on Wnt pathway targets 
For  semi-quantitative  analysis  of  changes  in 
target  protein  expression  after  pathway  inhibition, 
CCLP-1  cells  were  seeded  in  10  cm  diameter  Petri 
dishes and – after an overnight incubation step – ex-
posed to the individual inhibitors for 5 or 24 hrs in 
sfDMEM. Subsequent preparation of cell blocks after 
inhibitor  exposure,  basic  histology  and  immuno-
chemistry were performed as described recently [14]. 
From paraffin-embedded cell blocks, cylindrical 3 mm 
diameter  cores  were  obtained,  arranged  in  an  ar-
ray-like pattern and again embedded in paraffin. Five 
µm  sections  from  these  arrays  were  stained  for 
-catenin, cyclin D1, Ki67, p27, p53, E-Cadherin, and 
vimentin  as  described  previously  [14]  and  images 
were assessed independently by two experienced in-
vestigators (TK and DN). See Supplementary Materi-
al: Table S2 for details on antibodies and procedures. 
Statistics 
All data represent mean values of at least three 
independent  experiments  ±  SEM  (standard  error  of 
mean). Correlation analysis was performed by com-
parison of the efficiencies of the inhibitors with cellu-
lar  characteristics  (proliferation  and  differentiation 
markers) according to Pearson using PASW Statistics 
18.0.2  (SPSS  GmbH  Software,  Munich,  Germany). 
Paired t-test was used for calculation  of differences 
between treated and untreated samples for dose- (Fig. 
1) and cell line-dependent cytotoxicity (Fig. 2). Uni-
variate  ANOVA  and  the  LSD  (least  significant  dif-
ference) post hoc test were used for comparison be-
tween controls and treated cells for apoptosis induc-
tion (Fig. 4), cell cycle distribution (Fig. 5), Wnt re-
porter gene activity (Fig. 6), and target gene expres-
sion  analysis  (Fig.  7,  8).  For  all  calculations,  p<0.05 
and  p<0.01  was  considered  as  significant  or  highly 
significant, respectively. 
Results 
Dose-dependent cytotoxicity 
For investigation of the dose-dependent effect of 
the drugs, the CCLP-1 cell line that showed consid-
erable  cytotoxic  effects  for  all  inhibitors,  was  incu-
bated  with  varying  concentrations  of  each  inhibitor 
for  72  hrs.  All  substances  are  dissolved  in  DMSO 
which  shows  no  cytotoxicity  in  all  cell  lines  at  the 
concentrations used as determined in preceding con-
trol experiments (as solvent alone, data not shown). 
As shown in Figure 1, the drugs DMAT, FH525 and 
TBB (Fig. 1A) cause a clear dose-dependent reduction 
in  cell  viability  compared  to  untreated  control  cells 
resulting in a viability signal <10-20% at concentra-
tions of 10, 5, and 2 µM for TBB, DMAT and FH535, 
respectively.  
 
Figure 1. Dose-dependent cytotoxicity. CCLP-1 cells were 
incubated with increasing concentrations of DMAT, FH535, TBB 
(A) or myricetin, quercetin (B) in serum-free DMEM. After 72 hrs 
incubation at 37° C, the viability was measured using the resazurin 
assay and related to untreated controls (set to 100%). Significant 
(p<0.05) and highly significant (p<0.01) differences between the 
viability  signal  of  treated  cells  and  the  untreated  controls  are 
marked with *, †, § and **, ††, §§, respectively (paired t-test). Int. J. Biol. Sci. 2012, 8 
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For myricetin and quercetin (Fig. 1B), the cyto-
toxic effect is much less pronounced, since a signifi-
cant reduction to about 40 or 70% of controls can be 
obtained only at the highest concentrations (50 µM) of 
myricetin and quercetin, respectively. The IC50 values 
of  each  drug  are  estimated  by  linear  interpolation 
from Fig. 1A, B indicating the order of cytotoxic effi-
ciency as FH535 (1.1 µM) > DMAT (1.8 µM) > TBB (3.6 
µM), > myricetin (39.3 µM) > quercetin (not determi-
nable); see also Table 2 below.  
 
Cell line-dependent cytotoxicity 
Constant concentrations of each inhibitor (10 µM 
for DMAT and TBB, 20 µM for FH535, and 50 µM for 
myricetin and quercetin) were applied to nine differ-
ent BTC cell lines for 72 hrs followed by measurement 
of the cytotoxicity relative to untreated controls (set to 
0% toxicity) for each cell line. Figure 2A shows high 
toxicity of DMAT, FH535 and TBB of up to 90% cell 
killing  in  CCLP-1  and  CCSW-1  cells,  followed  by 
60-70% cytotoxicity in MzChA-1, MzChA-2, SkChA-1 
and GBC cells whereas lower levels of overall toxicity 
(35-50%) were found for BDC, EGI-1 and TFK cells. As 
expected from the results of Fig.1, overall toxicity of 
myricetin and quercetin is much lower in the range of 
20-30% for most cell lines (Fig. 2B) with some excep-
tions where up to 50% cytotoxicity are obtained for 
some  cell  line-drug  combinations  (e.g.  myricetin  in 
CCLP-1  and  quercetin  in  CCSW-1,  MzChA-2  and 
GBC cells).  
 
Relation of cytotoxicity to cellular phenotype 
Correlation analysis was used to relate the find-
ings  of  Fig.  2  to  general  parameters  of  the  cellular 
phenotype  such  as  differentiation  and  proliferation 
markers. As shown in Table 1, there is positive corre-
lation between the cytotoxicity of the individual in-
hibitors in the nine BTC cell lines. Cytoplasmatic or 
nuclear  localisation  of  -catenin  as  an  indicator  of 
active Wnt signalling [12, 29] shows a constant posi-
tive and in part significant correlation with the drug’s 
cytotoxicity.  In  contrast,  membranous  -catenin  lo-
calisation negatively correlates with the cytotoxic ef-
fect  exerted  by  each  of  the  inhibitors.  Comparison 
with  markers  of  cellular  differentiation  such  as  cy-
tokeratin and E-Cadherin expression indicates a con-
stant negative correlation with the cytotoxicity of the 
inhibitors. Especially for mRNA or protein levels of 
Ck7, Ck8, Ck19 and E-Cadherin the negative associa-
tion with the cytotoxic effect of individual inhibitors is 
(in part highly) significant.  
 
Figure  2.  Overall  cell  line-dependent  cytotoxicity.  Nine 
different biliary tract cancer cell lines were incubated with a single 
concentration of DMAT, FH535, TBB (A) or myricetin, quercetin 
(B) as indicated in the diagram in serum-free DMEM for 72 hrs at 
37° C. Afterwards, the resazurin assay was used to determine the 
cytotoxic  effect  (i.e.  loss  of  viability)  compared  to  untreated 
controls for each cell line (set to 0% toxicity). Significant (p<0.05) 
and highly significant (p<0.01) differences between the viability of 
treated cells and the untreated controls for each cell line are 
marked  with  *  and  **,  respectively  (paired  t-test).  For  better 
visualisation of the cytotoxic effect of each drug, values are given as 
relative cytotoxicity (control cells = 0%, i.e. 100% viability). 
 
Time-dependent cytotoxicity 
To investigate the temporal dynamics of the vi-
ability signal following incubation with the drugs, the 
resazurin assay was performed on CCLP-1 cells at 0, 
24, 48, and 72 hrs post incubation (Fig. 3). For all in-
hibitors the viability signal is significantly lower than 
that of untreated control cells at all time points after 
incubation. Of note, the signal drops below the start-
ing point (0 hrs, set to 1) after 24 hrs of incubation Int. J. Biol. Sci. 2012, 8 
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with DMAT, FH535 and TBB (Fig. 3A), whereas the 
viability  signals  after  incubation  with  quercetin  or 
myricetin  show  a  continuous  increase  (yet  slower 
than controls) or remain at the initial level (‘1’), re-
spectively.  
As a second independent approach, the xCEL-
Ligence system was employed to obtain real-time data 
on the cellular growth / cytotoxicity kinetics up to 72 
hrs after incubation with different concentrations of 
TBB and myricetin as representatives of drugs either 
inhibiting CK2 or showing other yet unspecified ef-
fects on Wnt / TCF signalling. As shown in Fig. 3 C, 
D, the four different concentrations of each drug re-
sult  in  a  clear  dose-dependent  response:  the  two 
higher concentrations of both drugs (5 / 10 µM for 
TBB and 25 / 50 µM for myricetin) cause a continuous 
drop in the cell index (i.e. the well impedance as a 
measure of cell attachment) down to 10-20% indicat-
ing pronounced morphological changes most proba-
ble attributable to apoptotic cell death (see below, Fig. 
4), i.e. rounding of cells accompanied by partial de-
tachment from the substrate. In contrast, the cell index 
curves for the two lower concentrations (1.25 / 2.5 µM 
for TBB and 6.25 / 12.5 µM for myricetin) end up at 
approximately  70%  and  60%  of  the  control  values, 
respectively. Subsequent analysis for IC50 values (see 
Table 2) provided values in the same order of mag-
nitude than those calculated from Fig. 1 A, B.  
 
 
Figure 3. Time-dependent viability. A, B. CCLP-1 cells were incubated with a single concentration of 10 µM DMAT, 20 µM FH535, 
10 µM TBB (A) or 50 µM myricetin, 50 µM quercetin (B) in serum-free DMEM. At 0, 24, 48 and 72 hrs post incubation, the resazurin assay 
was used to determine the changes in viability compared to untreated control cells (set to 0% toxicity). Significant (p<0.05) and highly 
significant (p<0.01) differences between signal of treated cells and the untreated controls for each cell line are marked with * and **, 
respectively (ANOVA, LDS post-hoc test). C, D. CCLP-1 cells were incubated with four different concentrations of TBB or myricetin in 
serum-free DMEM. The well impedance expressed by the cell index as a measure of viability was analysed using the xCELLigence system 
as described in the Material and Methods section. Data points are related to the untreated control sample for each time point (set to 
100%). Int. J. Biol. Sci. 2012, 8 
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Table 1. Correlation between drug cytotoxicity and the cellular phenotype of the nine BTC cell lines. 
 
a positive or negative correlation coefficients indicate a direct or indirect relationship between drug efficiency and the correlated parameter 
(e.g. marker expression), respectively 
b abbreviations: Cat, -catenin; Ck, cytokeratin; ECad, E-Cadherin; Myr, myricetin; Que, quercetin 
c correlation coefficient; * and ** indicate significant (p<0.05) and highly significant (p<0.01) correlations, respectively 
d according to Fig. 2 A, B. 
e see Supplementary Material: Table S3 for raw data 
Table 2. IC50 values of the compounds for CCLP-1 cells. 
 
a clinical trials on chemoprevention and dietary intervention for different tumours (www.clinicaltrials.gov)  
b estimated by linear interpolation between the data points around 50% cytotoxicity from Fig. 1 A, B  
c calculated from the data obtained at 72 hrs after incubation with different concentrations using the RTCA software 1.2.1 (Roche Applied 
Science) 
d n.c., not calculable, n.d., not determined Int. J. Biol. Sci. 2012, 8 
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Apoptosis induction and cell cycle analysis 
To further study the mode of cytotoxicity, two independent assays for apoptosis were performed (Fig. 4). 
The temporal dynamics of effector caspase-3/7 activation was measured at different time points after incubation 
as shown in Fig. 4 A, B (relative to total protein content). DMAT, FH535 and TBB show a clear time-dependent 
increase of the caspase signal which is highest for DMAT and significantly different than that of the control 
samples for all time points after incubation.  
 
Figure 4. Apoptosis induction. CCLP-1 cells were incubated with 10 µM DMAT, 20 µM FH535, 10 µM TBB (A, C) or 50 µM myricetin, 
50 µM quercetin (B, D) in serum-free DMEM and incubated for different periods. Caspase activity (A, B) was measured using a lumi-
nometric Caspase 3/7 assay as an indicator of apoptosis execution and related to the total protein content (a.u., arbitrary units). Nuclear 
fragmentation indicative of the late steps in the apoptotic process (C, D) was measured via fluorescence microscopy by Hoechst 33342 
nuclear staining. Condensed and fragmented nuclei were counted as apoptotic cells. Representative phase contrast and Hoechst fluo-
rescence microscopy images taken at 24 hrs after incubation are shown in E and F, respectively (scale bars indicate 50 µm). Significant 
(p<0.05) and highly significant (p<0.01) differences between signals (caspase signal or fractions of apoptotic nuclei) of treated cells and the 
untreated controls for each time point are marked with *, †, § and **, ††, §§ respectively (univariate ANOVA, LSD post-hoc test). Int. J. Biol. Sci. 2012, 8 
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The  temporal  dynamic  of  caspase  activation  is 
similar for myricetin and quercetin but the signal sig-
nificantly increases only after 24 or 32 hrs post incu-
bation. As an indicator of the late steps in the apop-
totic cascade, nuclear fragmentation was assessed at 6, 
24 and 32 hrs post incubation (see Fig. 4 E for sample 
images): Figure 4C indicates a continuous increase in 
the percentage of cells with condensed or fragmented 
nuclei for DMAT, FH535 and TBB with 20 and 40% (6 
hrs) and about 35 and 70% (32 hrs) for FH535, TBB or 
DMAT,  respectively.  Similar  values  but  with  a  de-
layed temporal course are found for myricetin, which 
is in contrast to cells incubated with quercetin where 
the extent of apoptotic nuclei is in the range of only 
10-15% (Fig. 4D).  
In accordance with these data, cell cycle analysis 
(Fig.  5)  performed  after  48  hrs  post  incubation 
demonstrates for DMAT, myricetin and TBB a signif-
icant  increase  of  cells  in  the  subG1  population  (i.e. 
decreased DNA content of apoptotic cells). A decrease 
of  the  cell  fraction  undergoing  DNA  replication  (S 
phase) is observable for myricetin. A similar, yet not 
significant  trend  to  an  increased  apoptotic  subG1 
population is also seen for FH535 and quercetin.  
 
 
 
 
 
Figure  5.  Cell  cycle  analysis.  CCLP-1 cells were incubated 
with either 10 µM DMAT, 20 µM FH535, 50 µM myricetin, 50 µM 
quercetin or 10 µM TBB in serum-free DMEM and incubated for 
48 hrs. Analysis of cell cycle distribution was performed using 
ethanol-fixed, RNase-treated and PI-stained cells by flow cytom-
etry. The percentage of cells in G0G1, S/G2, or below G0G1 (subG1 
fraction) cell cycle phases was analysed with the FlowMax software 
(Partec, Görlitz, Germany). The subG1 fraction is a measure of 
apoptotic cell death as these cells have undergone apoptotic DNA 
fragmentation. Significant (p<0.05) and highly significant (p<0.01) 
differences  between  population  sizes  of  treated  cells  and  the 
untreated controls for each cell cycle phase are marked with * and 
**, respectively (univariate ANOVA, LSD post-hoc test). 
Effect on Wnt specific transcription 
Based on the high cytotoxic efficiency of espe-
cially DMAT, FH535 and TBB, we further investigated 
whether these drugs have an influence on Wnt related 
transcriptional  activity.  To  test  this,  we  transfected 
CCLP-1 cells with a Wnt-specific reporter gene con-
struct based on a luciferase luminescence readout and 
incubated the cells with constant concentrations of the 
inhibitors. The signals obtained after 6 hrs incubation 
(Fig. 6) indicate a highly significant reduction to 20% 
of control levels for DMAT, FH535 and TBB. In con-
trast,  myricetin  does  not  change  TCF-dependent 
transcription and the values observed after quercetin 
treatment tend to be reduced, yet are not significantly 
different from that of control cells.  
 
 
Figure  6.  Wnt  reporter  gene  assay.  The Cignal Reporter 
gene assay was used to analyse the compound’s effects on Wnt 
pathway  specific  transcriptional  activity.  In  brief,  CCLP-1  cells 
were  transfected  with  the  reporter  construct  for  24  hrs  and 
afterwards treated with either 10 µM DMAT, 20 µM FH535, 50 
µM  myricetin,  50  µM  quercetin  or  10  µM  TBB  in  serum-free 
DMEM for 6 hrs. Additionally, positive and negative controls were 
included and treated as controls (without inhibitors). The lumi-
nescence signal was read as a dual luciferase with 'FF' and 'RR' 
indicating  the  Wnt-specific  (firefly  luciferase)  and  the  internal 
control signal (renilla luciferase), respectively. Significant (p<0.05) 
and highly significant (p<0.01) differences between the signals are 
marked  with  *  and  **,  respectively  (univariate  ANOVA,  LSD 
post-hoc test). 
 
Changes in Wnt target gene expression 
We finally tested the effect of the drugs on the 
expression  of  target  genes  and  selected  phenotypic 
markers on mRNA and protein level by qRT-PCR and 
semi-quantitative immunochemistry, respectively.  
As shown in Fig. 8 A, a reduction of overall ex-
pression of the -catenin protein is seen for DMAT, 
FH535 and TBB at both 5 and 24 hrs post treatment – a Int. J. Biol. Sci. 2012, 8 
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trend which is not observed for the mRNA levels (Fig. 
7 A). At 24 hrs post incubation, FH535 and TBB rather 
increase the mRNA level of -catenin. For quercetin, 
the protein levels of -catenin generally are similar to 
that of untreated controls; myricetin reduces  its ex-
pression after 24 hrs of treatment. 
The anti-proliferative effects of the inhibitors are 
corroborated by reduced protein expression of cyclin 
D1  and  the  proliferation  marker  Ki67  (Fig.  8  B,  C) 
showing  significant  changes  for  the  majority  of 
treatments except quercetin at 24 hrs. In accordance 
with  these  data,  protein  levels  of  the  p27  cell  cycle 
inhibitor (Fig. 8 D) as another negative target of Wnt 
signalling are increased especially at early time points 
after  treatment.  These  changes  are  in  part  also  ob-
servable in the data on mRNA expression (Fig. 7 B, C). 
Additionally, we measured overall expression of p53 
protein as an indicator of active apoptosis signalling 
and vimentin as a mesenchymal marker. In line with 
data on apoptosis induction, the p53 protein shows 
increased expression especially after 24 hrs of treat-
ment  for  all  drugs  except  quercetin.  Of  note,  the 
mesenchymal  marker  protein  vimentin  which  is 
highly expressed in untreated control cells shows a 
reduction of up to 50% (FH535, TBB) – again, an effect 
which is more pronounced at later time points after 
incubation. Similar to the situation with -catenin, this 
tendency cannot be seen in mRNA expression levels 
of vimentin (Fig. 7D). E-Cadherin as the correspond-
ing epithelial  marker shows an opposite behaviour: 
while barely or not detectable on mRNA or protein 
levels  in  control  cells,  drug  treatment  causes  an 
up-regulation of its expression, especially on mRNA 
levels for DMAT, FH535 and TBB (Fig. 7H, 8G).  
 
 
Figure 7. Effect on target mRNAs. Quantitative real-time reverse transcription PCR was used to investigate the compound’s effect 
on expression of potential Wnt pathway target genes. CCLP-1 cells were treated with either 10 µM DMAT, 20 µM FH535, 50 µM 
myricetin, 50 µM quercetin or 10 µM TBB in serum-free DMEM for 5 or 24 hrs. Afterwards, total mRNA was isolated and quantified by 
qRT-PCR relative to -actin as the housekeeping gene (see Material and Methods section for details). Values are given as 2-Ct, where 
Ct=Ct(x)-Ct(housekeeping gene) with -actin as the housekeeping gene. Significant (p<0.05) and highly significant (p<0.01) differences between 
expression in treated versus control cells are marked with * and **, respectively (univariate ANOVA, LSD post-hoc test). Abbreviations: 
n.d., not determinable. 
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Figure 8. Effect on target proteins. Semi-quantitative immunochemistry was used to investigate the compound’s effect on expression 
of potential Wnt pathway target genes. CCLP-1 cells were treated with either 10 µM DMAT, 20 µM FH535, 50 µM myricetin, 50 µM 
quercetin or 10 µM TBB in serum-free DMEM for 5 or 24 hrs. Afterwards, cell blocks were prepared, fixed in formalin and subjected to 
standard immunochemistry. Staining intensity was used for discrimination of positive versus negative cells. Significant (p<0.05) and highly 
significant (p<0.01) differences between percentages of positive cells within treated samples and the untreated control for each time point 
are marked with *, † and **, †† respectively (univariate ANOVA, LSD post-hoc test). 
 
 
On mRNA level we additionally determined the 
expression of TCFL1 and -L2 (Fig. 7 E, F) as two major 
transcription  factors  responsible  for  regulation  of 
target gene transcription following Wnt pathway ac-
tivation. Interestingly, DMAT can significantly reduce 
their expression at 5h post incubation – however, at 
later time points (24 hrs) the levels of these mRNAs 
are either (in part significantly) increased or similar to 
the untreated control in case of myricetin. A similar 
trend is observable for axin2 which is another direct 
target  of  Wnt  signalling:  while  DMAT  can  signifi-
cantly reduce axin2 mRNA levels after 5 hrs, the ex-
pression level at 24 hrs post treatment is higher than 
in the untreated control sample (Fig. 7D). 
Discussion 
In the present study we tested a panel of small 
molecular  weight  compounds  with  previously  re-
ported inhibitory effects on Wnt signalling for their 
anti-cancer activity in BTC cells in an in vitro model. 
Of the substances used – DMAT, FH535, TBB, myri-
cetin,  and  quercetin  (see  Table  2  for  their  chemical 
structures and characteristics) – the first three signifi-
cantly cause efficient cytotoxicity, apoptosis induction 
and reduction of Wnt-specific reporter gene activity, 
whereas cytotoxicity is less pronounced for myricetin 
and quercetin which are, furthermore, characterised 
by a delayed time course of apoptosis induction. Ef-
fects  on  target  gene  expression  include 
down-regulation of cell cycle-promoting factors such 
as cyclin D1 as well as up-regulation of the prolifera-
tion inhibitor p27 and are consistent with the known 
molecular targets of Wnt signalling [12, 31, 32]. The 
concentrations  used  in  this  study  are  similar  to  ex-
amples previously reported, i.e. 10 µM for DMAT [18, 
33] and TBB (e.g. [18]), 20 µM for FH535 [19] and 50 
µM for myricetin and quercetin [34]. Int. J. Biol. Sci. 2012, 8 
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In  contrast  to  the  single  target  specificity  of 
(monoclonal) antibody-based therapies, small molec-
ular weight inhibitors usually have several molecular 
targets implicating that overall cellular responses may 
be a result of the multiple actions of these drugs. For 
example,  Boly  et  al.  [35]  reported  on  the  effects  of 
quercetin used at 10% of its IC50 growth-inhibitory 
concentration in eight different cell lines on multiple 
kinases and found that the activity was reduced by 
>80% for 16 kinases most of which are involved in 
control of mitotic processes [35]. This is also valid for 
casein kinase II inhibitors (DMAT, TBB) as this pro-
tein  has  several  tumourigenic  functions  which  may 
not exclusively rely on its involvement in Wnt signal-
ling  [36].  Similarly,  myricetin  has  effects  on  several 
different  signalling  mechanisms  including  ERK1/2 
[37],  c-FLIP  and  Bcl-2  [38],  Akt  [39],  DNA  topoiso-
merases I and II [40], as well as JAK1 [41]. Although 
such  off-target  effects  cannot  be  excluded  for  these 
compounds in the BTC cell lines, at least for DMAT, 
FH535  and  TBB  the  Wnt  transcription-specific  re-
porter assay results suggests that some of their cyto-
toxic action is based on blocking of Wnt target gene 
transcription. These results are in line with Handeli et 
al.  who  reported  that  FH535  down-regulates 
-catenin-TCF/LEF-dependent  transcription  and  is 
effective  only  in  cell  lines  that  express  the  Wnt  / 
-catenin pathway [19]. Recently, a study by Vaid et 
al.  could  show  reduced  nuclear  accumulation  of 
-catenin in melanoma cell lines after treatment with 
FH535 [42]. Furthermore, active CK2 is a prerequisite 
for Wnt signal transduction in the cytoplasm [20, 21] 
and causes increased expression of the anti-apoptotic 
protein survivin via a -catenin-TCF/LEF-dependent 
transcription [43].  
As expected from the dose-dependent viability 
analysis using one representative cell line (CCLP-1) 
the overall cytotoxicity of myricetin and quercetin is 
less pronounced in the panel of nine BTC cell lines. 
For DMAT, FH535 and TBB cytotoxicity is >60% in six 
of nine cell lines and at least 40% in three of the nine 
cell  lines.  This  suggests  that  these  compounds  are 
highly  effective  in  most  BTC  cellular  phenotypes 
whereas myricetin and quercetin, at best, show mod-
erate  effects.  Additionally,  the  cytotoxicities  of  the 
more  effective  drugs  (DMAT,  FH535  and  TBB)  are 
positively correlated indicating that cell lines respon-
sive to either DMAT, FH535 or TBB also respond to 
treatment with one of the other two drugs. Although 
correlation  analysis  with  the  cellular  phenotype  as 
well  as  the  intracellular  protein  localisation  of 
-catenin indicates that the cytotoxicity is more pro-
nounced  in  cells  with  rather  cytoplasmatic  and  nu-
clear -catenin – i.e. active Wnt pathway – as well as 
in  undifferentiated  cells  (low  cytokeratin  and 
E-Cadherin expression) the current results could not 
identify  a  molecular  factor  within  the  analysed  pa-
rameters  which  can  unequivocally  predict  the  re-
sponse towards these drugs. As this study uses over-
all  viability  and  apoptosis  induction  as  summative 
measures of the drug efficiencies, additional factors 
such  as  differential  uptake  into  or  export  from  the 
cells cannot be excluded to influence the cellular ef-
fects of these drugs. As reported in previous studies, 
BTC tissue may harbour specific mutations in genes 
involved in Wnt signal transduction [17]. Therefore, 
the impact of Wnt component mutations need to be 
investigated in subsequent studies in order to obtain a 
causative explanation for the differential drug sensi-
tivity seen in the current panel of BTC cell lines.  
Time course analysis of the viability indicates a 
significantly  reduced  amount  of  viable  cells  for  all 
treatments beginning at 24 hrs post  incubation. For 
DMAT,  FH535  and  TBB  the  viability  signals  drops 
below the initial value (‘0 hrs’, at incubation) indicat-
ing a direct cytotoxic response towards these agents. 
A complementary assay was performed for TBB and 
myricetin  using  the  xCELLigence  system  allowing 
real-time analysis of the temporal cellular dynamics in 
a  label-free  manner.  These  data  essentially  confirm 
those  obtained  with  the  classical  viability  test  by 
showing a continuous drop in the cell index for the 
higher concentrations of the drugs and furthermore, 
by providing similar values for the IC50 concentra-
tion. For myricetin the reduction of the cell index is 
more pronounced than expected from the resazurin 
assay  which  indeed  shows  a  significantly  reduced 
viability compared to control cells, but a rather con-
stant  signal  up  to  72  hrs  post  incubation.  This  dis-
crepancy can be explained by the fact that apoptotic 
cells are characterised by active metabolic processes 
until late steps in the apoptotic programme [44], i.e. 
show a high activity in enzyme-based viability tests 
such as MTT and resazurin while morphological fea-
tures such as rounding and blebbing are already in 
progress and cause reduction in the cell index in the 
xCELLigence system.  
To further investigate whether the reduction in 
overall viability is attributable to induction of apop-
tosis,  we  analysed  independent  hallmarks  of  apop-
totic cell death including activation of effector caspa-
ses  (capase-3/7),  changes  in  cellular  and  nuclear 
morphology, i.e. rounding and cell blebbing as well as 
nuclear fragmentation, and appearance of cells with 
reduced DNA content in flow cytometry analysis. All 
inhibitors  cause  an  increase  in  caspase  activity 
whereas  morphological  changes  and  nuclear  frag-
mentation are most predominant in cells treated with Int. J. Biol. Sci. 2012, 8 
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DMAT, FH535 and TBB. For myricetin and quercetin, 
this may be due to the lower level (and slightly de-
layed  course)  of  apoptosis  induction  which  can  be 
seen in the caspase-3/7 time course. Several previous 
publications  reported  apoptosis-inducing  activities 
for these compounds: e.g. for myricetin / quercetin in 
oesophageal  carcinoma  cells  [34],  keratinocytes  [35] 
and human leukaemia cells [45]; for DMAT / TBB in 
C6  glioma  [46],  adrenocortical  carcinoma  [47]  leu-
kaemia [18], and MCF-7 breast cancer cells [33]. For 
FH535 only data from the initial publication [19] are 
available where a larger panel of cell lines were tested 
for the drug’s effects in a  3H uptake assay – yet no 
assay for apoptosis was performed. When used with 
hepatocellular carcinoma cell lines [48], DMAT effec-
tively reduced proliferation whereas no induction of 
apoptosis  was  found  –  however,  more  importantly, 
this study provided preliminary data on the in vivo 
anti-tumour activity of this drug [48]. 
Analysis of the target gene expression on protein 
level  indicates  a  uniform  and  significant 
down-regulation  of  cell  cycle-promoting  cyclin  D1 
and  the  proliferation  marker  Ki67,  whereas  the  cell 
cycle inhibitor p27 shows enhanced expression. These 
effects are most clear for DMAT, FH535 and TBB, and 
less  pronounced  for  myricetin  and  quercetin.  Alt-
hough all inhibitors induce apoptosis as determined 
by caspase activation and nuclear fragmentation, this 
additional  growth-inhibitory  effect  is  in  agreement 
with the finding from time-dependent viability anal-
ysis where myricetin and quercetin tend to be rather 
growth-inhibitory during the early time points after 
incubation.  The  protein  levels  of  -catenin  are  re-
duced in a significant portion of cells, especially after 
treatment with DMAT, FH535 and TBB correspond-
ing to the results of the reporter gene assay thus sug-
gesting that some of their effects are based on inhib-
iting  Wnt  pathway  activity.  Analysis  of  the  mRNA 
expression of the Wnt transcription factors TCF7L1, 
-L2  and  axin2  indicates  that  DMAT  reduced  their 
abundance at early time points after incubation fol-
lowed  by,  however,  an  increased  expression  com-
pared to controls at 24 hrs. This dynamics seems sim-
ilar to the situation for mRNA expression of -catenin 
which  could  be  interpreted  as  a  compensatory 
mechanism, i.e. in cells still viable at 24 hrs post in-
cubation,  an  attempt  is  made  to  overcome  the 
Wnt-inhibitory  effects  of  the  compounds  by 
over-expression  of  Wnt  pathway  components.  This 
hypothesis  yet  needs  confirmation  by  detailed 
time-resolved  studies  including  quantitative  protein 
determination in case of the transcription factors. 
Taken together, the current report provides evi-
dence, that especially DMAT, TBB and FH535 (as well 
as myricetin and quercetin, albeit to a lesser extent) 
show considerable cytotoxic effects in BTC cells and – 
in case of DMAT, FH535 and TBB – that these effects 
are  associated  with  inhibition  of  Wnt-dependent 
transcription. As a limitation of this study, no data on 
the in vivo efficiency of these drugs are yet available 
which obviously are required before considering the-
se compounds for clinical trials in BTC patients. Alt-
hough DMAT, FH535 and TBB show substantial cy-
totoxicity in all BTC cell lines it, furthermore, remains 
to be investigated which phenotypic feature could be 
used as a marker indicating which actual BTC phe-
notype is particularly susceptible towards treatment 
with these drugs. Further investigation based on the 
current  data  seems  of  special  interest  for  BTC  as  a 
specific CK2 inhibitor (CX-4945, [49]) is available and 
currently  undergoes  initial  clinical  investigation  for 
other cancers.  
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